SIGLECL1

Across TCGA pan-cancer cohorts, SIGLECL1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SIGLECL1’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SIGLECL1 RNA is repressed in tumor relative to normal tissue. In most cancer types SIGLECL1 is over-expressed in tumor, although a few such as BRCA and STAD show the opposite, repressed pattern.

BRCA, KIRP, and LUAD are the cancer types where SIGLECL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIGLECL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	−0.010	.002	6	view →
KIRP	Male	All	+0.016	.019	2	view →
LUAD	All	All	+0.028	.039	1	view →
LIHC	Female	All	+0.012	.026	1	view →
STAD	Male	II,III,IV	−0.008	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SIGLECL1–BRCA

Open the BRCA breakdown →